Clinical Trials Logo
  1. Home
  2. Refractory Chronic Cough
  3. NCT02612623

An 8-Week Refractory Chronic Cough Study (MK-7264-021)

Refractory Chronic Cough Clinical Trial

Official title:
A Randomized, Parallel, Double-Blind Study to Assess the Efficacy and Tolerability of AF-219 in Subjects With Refractory Chronic Cough

Clinical Trial Summary

This was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (AF-219) in participants with refractory chronic cough.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02612623
Study type Interventional
Source Afferent Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 2
Start date December 17, 2015
Completion date May 18, 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT03282591 - Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough Phase 2
Completed NCT03407014 - Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) Phase 2
Completed NCT02476890 - Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) Phase 2
Recruiting NCT05599191 - A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Phase 3
Recruiting NCT03662269 - Indomethacin for Refractory Chronic Cough Phase 3
Recruiting NCT05962151 - Refractory Chronic Cough Improvement Via NAL ER (RIVER) Phase 2
Recruiting NCT05110144 - Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough Phase 2
Active, not recruiting NCT04882943 - COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database
Enrolling by invitation NCT05733533 - A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough Phase 2
Completed NCT02349425 - A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) Phase 2
Recruiting NCT05600777 - A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2) Phase 3
Completed NCT05628740 - Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175 Phase 1
Not yet recruiting NCT06213363 - A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough Phase 1/Phase 2
Completed NCT02412020 - Treatment of Refractory Chronic Cough With PA101 Phase 2
Completed NCT04678206 - Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Phase 2
Completed NCT02612610 - A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) Phase 2
Completed NCT02397460 - Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015) Phase 2
Not yet recruiting NCT05265871 - ATP Level and Cough Sensitivity to ATP in Subjects With Refractory Chronic Cough